Skip to main content
. Author manuscript; available in PMC: 2016 Mar 15.
Published in final edited form as: Clin Cancer Res. 2015 Jan 14;21(6):1447–1456. doi: 10.1158/1078-0432.CCR-14-1773

Figure 3. Recurrently altered pathways in metastatic cSCC.

Figure 3

Pathway diagrams depicting the percentage of samples with alterations in

3A - RAS/RAF/MEK/ERK and PI3K/AKT signaling

3B - cell cycle, and

3C - squamous cell differentiation

Alterations are classified as activating (high-level amplification or known activating mutation colored red), inactivating (homozygous loss or truncating mutation colored blue), or potentially cancer associated (COSMIC mutation colored white). For each pathway, we show integrated heatmaps (similar to Fig 1B) to show the detailed alteration pattern of each gene; however, we now also include light red and light green to represent low-level CNAs. Note that each heatmap is sorted independently across the samples, to best illustrate the pattern of mutations, such as mutual exclusivity or concurrence.